GLP-1 medications carry a warning for individuals with medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). These medications are linked to C-cell growth in animal studies, which has been observed to cause tumors.
Important Considerations for Patients
Despite a large Scandinavian study showing no substantial increase in thyroid cancer among GLP-1 users, the FDA advises against these medications for those at elevated risk of MTC. MEN2, often associated with MTC, also presents a risk. If you take thyroid hormone replacement medication like levothyroxine, adjustments to your daily routine may be necessary when starting an oral GLP-1 to ensure effective absorption. Wegovy and Foundayo tablets must be taken on an empty stomach with specific timing considerations.
Monitoring and Management
Levothyroxine should generally not be taken simultaneously with these oral GLP-1s. Individuals with common thyroid conditions such as goiter, Graves’ disease, or hypothyroidism generally do not require avoidance of GLP-1s, but should discuss their medical history with their doctor. Thyroid hormone levels should be monitored regularly, and changes in weight can influence levothyroxine dosage. Questions to ask your doctor include the type of thyroid condition, family history of MTC or MEN2, and the need for genetic testing.